CAESAREA, Israel, March 19, 2017 /PRNewswire/ --
Itamar Medical Ltd. (TASE: ITMR) wishes to clarify its recent pressrelease, "An Important Recognition in the US Market for the WatchPAT™ Device" from March 16th.
Certain language in the press release mistakenly implies that the new AASM clinical practice guideline formally endorses
Itamar Medical wishes to publicly and sincerely apologize for any potential misunderstanding and inconvenience this caused to the AASM, its members or their patients.
About Itamar Medical Ltd.
Itamar Medical Ltd. is a publicly traded medical device company (TASE:ITMR) that develops and markets innovative diagnostic and therapy solutions for sleep breathing disorders and cardiovascular conditions.
Contact: Gilad Glick Chief Executive Officer and President T: +972-4-6177000 firstname.lastname@example.org
SOURCE Itamar Medical Ltd
Subscribe to our Free Newsletters!
Malaria is a dangerous disease with lethal consequences that requires protective measures for ...
Merkel cell carcinoma is a rare and a highly aggressive primary skin cancer that grows rapidly and ...
Vitrectomy is a surgical procedure performed to remove a part or whole of the vitreous humor ...View All